If you experienced sudden or gradual vision loss while taking any GLP-1 medication there is now significant and growing scientific evidence linking semaglutide to NAION — a serious optic nerve condition. Two independent peer-reviewed studies from Harvard and Danish researchers have confirmed the association.
A landmark 2024 study from Harvard Medical School examined a large cohort of patients with diabetes and obesity. Researchers compared rates of NAION between patients taking semaglutide and those taking other medications for the same conditions. The semaglutide group had a statistically significant higher rate of NAION diagnosis — not a marginal finding but a clear and robust result published in a major peer-reviewed journal after rigorous independent review.
A separate Danish registry study in JAMA Ophthalmology reached similar conclusions using completely independent data from a different country and patient population. When two independent large-scale studies using different methodologies and populations reach the same conclusion the scientific community considers this convergent evidence substantially more reliable than a single study alone. In 2026 a third study in JAMA Ophthalmology found semaglutide users were twice as likely to develop neovascular age-related macular degeneration — a separate condition that progressively destroys central vision. The accumulation of peer-reviewed evidence is now substantial enough that ophthalmologists are formally calling on the FDA to require a black box warning on all semaglutide medications.
NAION occurs when blood supply to the optic nerve is suddenly disrupted. The optic nerve receives blood through very small vessels in a crowded anatomical space. When blood flow drops below the threshold needed to maintain nerve tissue health the nerve begins experiencing ischemic damage — essentially the same process as a heart attack but occurring in the optic nerve. Researchers believe semaglutide may contribute through its significant blood pressure lowering effects. For individuals with anatomical predispositions the additional blood pressure reduction may push optic nerve blood flow below the survival threshold particularly during sleep when pressure is naturally lowest.
The classic presentation of NAION is sudden painless vision loss — typically noticed first thing in the morning upon waking. Vision loss may manifest as a dark area or blind spot in part of the visual field blurring or darkening across the entire visual field of the affected eye or complete loss of light perception in severe cases. The painless nature causes many patients to delay seeking emergency care expecting serious vision loss to hurt. If you experienced sudden vision changes during GLP-1 use seek ophthalmological evaluation even if the episode occurred some time ago.
Several conditions can cause sudden vision loss and some patients with NAION are initially misdiagnosed. If you experienced sudden vision loss during GLP-1 use and are uncertain about the diagnosis a second opinion from a neuro-ophthalmologist is strongly recommended. If the timing of your vision change coincides with your medication use your situation is worth having reviewed by a legal professional regardless of the specific diagnosis given.
90 seconds. No cost. No obligation. A specialist contacts you within 24 hours.